Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.
Surg Today. 2010 Sep;40(9):851-7. doi: 10.1007/s00595-009-4154-y. Epub 2010 Aug 26.
Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites. We conducted this experimental study to find out if bevacizumab, a humanized monoclonal antibody against VEGF, had a suppressive effect on peritoneal dissemination from gastric cancer, in an experimental nude mouse model of peritoneal metastasis.
Each mouse was treated with a single intraperitoneal (i.p.) injection of bevacizumab. Five mice were killed, and we measured their body weight, the mean number of tumor nodules, and the volume of ascites. We also extracted retroperitoneal tissues for histological examination, to count the frequency of mitosis, and to calculate the mitotic index. Another five mice were monitored until death, and their mean survival duration was calculated.
The volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group (P = 0.042 and P < 0.01, respectively). The survival curve of the therapy group was significantly higher than that of the nontherapy group (P = 0.005).
Bevacizumab may suppress peritoneal dissemination from gastric cancer.
血管内皮生长因子（VEGF）已被报道能增强腹壁的血管通透性和血管生成，从而促进伴有恶性腹水的腹膜扩散。我们进行了这项实验研究，以了解抗 VEGF 人源化单克隆抗体贝伐单抗是否对胃癌腹膜转移的实验裸鼠模型中的腹膜扩散具有抑制作用。
每只小鼠接受单次腹腔内（i.p.）注射贝伐单抗。处死 5 只小鼠，测量其体重、肿瘤结节的平均数量和腹水体积。我们还提取腹膜后组织进行组织学检查，以计数有丝分裂的频率，并计算有丝分裂指数。另外 5 只小鼠被监测至死亡，并计算其平均存活时间。
治疗组的腹水体积和有丝分裂指数明显低于非治疗组（P=0.042 和 P<0.01）。治疗组的生存曲线明显高于非治疗组（P=0.005）。
贝伐单抗可能抑制胃癌的腹膜扩散。
